Notably, consistent with data seen in FIGHT-202 where none of nine patients with cholangiocarcinoma and concurrent TP53 mutations showed an objective response26, in FIGHT-207 none of 27 FGFR-altered tumors of various histologies with concurrent TP53 mutations detected in tumor tissue showed an objective response to pemigatinib. Here, TP53 is linked to cholangiocarcinoma.